for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Hookipa Pharma Inc

HOOK.OQ

Latest Trade

10.69USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

5.80

 - 

14.33

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
10.69
Open
--
Volume
--
3M AVG Volume
1.58
Today's High
--
Today's Low
--
52 Week High
14.33
52 Week Low
5.80
Shares Out (MIL)
25.64
Market Cap (MIL)
269.53
Forward P/E
-5.66
Dividend (Yield %)
--

Latest Developments

More

Hookipa Announces Positive Phase 2 Results For Cmv Vaccine Candidate Hb‑101

Hookipa Pharma Reports Quarterly Loss Per Share Of 43 Cents

Hookipa Pharma Reports Q4 Loss Per Share Of $0.40

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Hookipa Pharma Inc

HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is developing products to prevent and cure infectious diseases and cancer. The Company's infectious and oncology product candidates HB-101, HB-201 and HB-202. The infectious disease product candidate, HB-101, is in a randomized, double-blinded Phase II clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates, HB-201 and HB-202, are in development for the treatment of human papillomavirus-positive cancers. The Company offers VaxWave technology, which is designed to induce a robust CD8+ T cell and pathogen neutralizing response to fight disease. VaxWave technology supports the benefits of our arenavirus platform approach.

Industry

Biotechnology & Drugs

Contact Info

430 East 29Th Street, 14Th Floor

NEW YORK, NY

10016-8367

United States

+1.302.6555049

https://www.hookipapharma.com/

Key Stats

1.40 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2019

0.0K

2020(E)

0.0K
EPS (USD)

2019

-2.410

2020(E)

-1.858
Price To Earnings (TTM)
--
Price To Sales (TTM)
20.11
Price To Book (MRQ)
2.47
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
3.73
LT Debt To Equity (MRQ)
3.59
Return on Investment (TTM)
-43.03
Return on Equity (TTM)
-37.52

Latest News

Latest News

BRIEF-Hookipa Announces Positive Phase 2 Results For Cmv Vaccine Candidate Hb‑101

* HOOKIPA ANNOUNCES POSITIVE PHASE 2 INTERIM SAFETY AND IMMUNOGENICITY RESULTS FOR ITS CMV VACCINE CANDIDATE HB-101

BRIEF-Hookipa Says Board Of Directors Will Consist Of Eight Members

* HOOKIPA ANNOUNCES CHANGES TO ITS BOARD OF DIRECTORS – RESIGNATION OF SANDER VAN DEVENTER

BRIEF-Hookipa Announces FDA Clearance Of Ind Application For Hb-202/201 Clinical Trial To Treat Hpv-Positive Cancers

* HOOKIPA ANNOUNCES FDA CLEARANCE OF ITS IND APPLICATION FOR HB-202/201 CLINICAL TRIAL TO TREAT HPV-POSITIVE CANCERS

BRIEF-Hookipa Pharma Files For Mixed Shelf Offering Of Up To $200 Million

* HOOKIPA PHARMA FILES FOR MIXED SHELF OFFERING OF UP TO $200 MILLION - SEC FILING Source text: (https://bit.ly/361WaOo) Further company coverage:

BRIEF-Hookipa Pharma Reports Quarterly Loss Per Share Of 43 Cents

* HOOKIPA PHARMA REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE

BRIEF-Hookipa Pharma Reports Q4 Loss Per Share Of $0.40

* HOOKIPA PHARMA REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up